Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 9/20 | 0.59 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.54 |
| ▸ | REN | P00797 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19696469 | 1.00 | CTSD (0.59) | CTSDKLK5RENCTSLCTSB | |
| SCHEMBL17969295 | 0.91 | CTSD (0.62) | CTSDKLK5REN | |
| SCHEMBL17969293 | 0.91 | CTSD (0.62) | CTSDKLK5REN | |
| SCHEMBL17969292 | 0.91 | CTSD (0.62) | CTSDKLK5REN | |
| SCHEMBL17770741 | 0.91 | CTSD (0.64) | CTSDKLK5RENCTSB | |
| SCHEMBL17969294 | 0.91 | CTSD (0.62) | CTSDKLK5REN | |
| SCHEMBL17969290 | 0.91 | CTSD (0.62) | CTSDKLK5REN | |
| SCHEMBL12475208 | 0.90 | CTSD (0.70) | CTSDKLK5RENCTSB | |
| SCHEMBL17770740 | 0.90 | CTSD (0.65) | CTSDKLK5RENCTSLCTSB | |
| SCHEMBL19696442 | 0.90 | CTSD (0.56) | CTSDKLK5RENCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9839665-B2 | Aminostatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2017-12-12 | — | — | US | disclosed |
| US-9839665-B2 | Aminostatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2017-12-12 | — | — | US | disclosed |
| US-20160228493-A1 | AMINOSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-20160228493-A1 | AMINOSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-9345742-B2 | Aminostatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2016-05-24 | — | — | US | disclosed |
| US-9345742-B2 | Aminostatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2016-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228493-A1 | AMINOSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | CTSD, CTSB, CTSZ | CTSD 1/4885KLK5 496/4885REN 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.